PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34681815-3	2021	We recently identified fexofenadine, a well-known antagonist of histamine H1 receptor, as a novel inhibitor of TNFalpha signaling.	fexofenadine	23-35	tumor necrosis factor	Mus musculus	111-119	
34681815-4	2021	Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine-mediated anti-TNF activity relied on cPLA2 in vitro.	fexofenadine	103-115	tumor necrosis factor	Mus musculus	130-133	
31302596-0	2019	Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.	fexofenadine	0-12	tumor necrosis factor	Mus musculus	22-25	
31302596-3	2019	METHODS: In vitro and in vivo screening of an Food and Drug Administration (FDA)-approved drug library; in vitro and in vivo assays for examining the blockade of TNF actions by fexofenadine: assays for defining the anti-inflammatory activity of fexofenadine using TNF-alpha transgenic (TNF-tg) mice and collagen-induced arthritis in DBA/1 mice.	fexofenadine	177-189	tumor necrosis factor	Mus musculus	162-165	
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	54-66	tumor necrosis factor	Mus musculus	364-367	
31302596-5	2019	RESULTS: Serial screenings of a library composed of FDA-approved drugs led to the identification of fexofenadine as an inhibitor of TNF-alpha signalling.	fexofenadine	100-112	tumor necrosis factor	Mus musculus	132-141	
31302596-8	2019	Fexofenadine blocked TNF-stimulated cPLA2 activity and arachidonic acid production through binding to catalytic domain 2 of cPLA2 and inhibition of its phosphorylation on Ser-505.	fexofenadine	0-12	tumor necrosis factor	Mus musculus	21-24	
31302596-9	2019	Further, deletion of cPLA2 abolished fexofenadine"s anti-TNF activity.	fexofenadine	37-49	tumor necrosis factor	Mus musculus	57-60	
31302596-10	2019	CONCLUSION: Collectively, these findings not only provide new insights into the understanding of fexofenadine action and underlying mechanisms but also provide new therapeutic interventions for various TNF-alpha and cPLA2-associated pathologies and conditions, particularly inflammatory rheumatic diseases.	fexofenadine	97-109	tumor necrosis factor	Mus musculus	202-211